Geratherm Medical AG (XTER:GME) Total Liabilities : €14.97 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Geratherm Medical AG Total Liabilities?

Geratherm Medical AG's Total Liabilities for the quarter that ended in Jun. 2023 was €14.97 Mil.

Geratherm Medical AG's quarterly Total Liabilities declined from Sep. 2022 (€18.48 Mil) to Dec. 2022 (€16.15 Mil) and declined from Dec. 2022 (€16.15 Mil) to Jun. 2023 (€14.97 Mil).

Geratherm Medical AG's annual Total Liabilities declined from Dec. 2020 (€16.07 Mil) to Dec. 2021 (€14.47 Mil) but then increased from Dec. 2021 (€14.47 Mil) to Dec. 2022 (€16.15 Mil).

Geratherm Medical AG Total Liabilities Historical Data

The historical data trend for Geratherm Medical AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geratherm Medical AG Total Liabilities Chart

Geratherm Medical AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Liabilities

Get a 7-Day Free Trial

9.57

14.08

16.07

14.47

16.15

Geratherm Medical AG Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Total Liabilities	Get a 7-Day Free Trial															16.86	17.60	18.48	16.15	14.97

Geratherm Medical AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Geratherm Medical AG's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2.185	+	(9.295	+	4.672
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	16.15

Total Liabilities	=	Total Assets (A: Dec. 2022 )	-	Total Equity (A: Dec. 2022 )
	=	38.38	-	22.228
	=	16.15

Geratherm Medical AG's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.684	+	(8.15	+	5.136
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	14.97

Total Liabilities	=	Total Assets (Q: Jun. 2023 )	-	Total Equity (Q: Jun. 2023 )
	=	38.219	-	23.249
	=	14.97

Geratherm Medical AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of Geratherm Medical AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Geratherm Medical AG (XTER:GME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Geratherm Medical AG (XTER:GME) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GME:Germany

Address

Fahrenheitstrasse 1, Geratal, DEU, 99331

Website

https://www.geratherm.com

Geratherm Medical AG is a Germany-based medical technology company. The firm operates through four segments: Healthcare Diagnostic, Medical Warming Systems, Cardio/Stroke and Respiratory. Healthcare Diagnostic segment which generates majority revenue provides analog and digital products for measuring body temperature, blood pressure monitors and other products for measuring temperature, as well as related accessories. Medical Warming Systems offers solutions for temperature management at all stages in the pre-clinical and clinical care of the patients, such as rescue situations and operations. Cardio/Stroke segment comprises products for preventing strokes. The Respiratory segment focuses on the development and production of products for pulmonary functional diagnostics.

Executives